Radioactive antibody hones in on cancer cells to boost transplant success

NCT ID NCT05139004

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether adding a radioactive antibody (90Y-DOTA-anti-CD25 basiliximab) to standard chemotherapy and targeted radiation can better prepare the bone marrow for a stem cell transplant in people with high-risk acute leukemia or myelodysplastic syndrome. The antibody seeks out and destroys cancer cells carrying the CD25 marker, while the chemo and radiation clear space for donor cells. The goal is to find the safest dose and see if this combination improves transplant outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
90Y-DOTA-anti-CD25 basiliximab (radioactive antibody)
What this could lead to
If it works, this approach could improve the success of stem cell transplants for people with hard-to-treat leukemia or MDS.
What could go wrong
This is an early-phase trial with only 7 participants, so the dose and safety are still being figured out. Radioactive and chemotherapy drugs can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.